| 孙丽秀 高宇囡 支继新 许圆圆 李学奇.rhBNP 在心力衰竭合并肾功能不全中的应用前景[J].,2015,15(6):1189-1191 |
| rhBNP 在心力衰竭合并肾功能不全中的应用前景 |
| Application Prospect of rhBNP in Heart Failure and Renal Insufficiency |
| |
| DOI： |
| 中文关键词: 心力衰竭 重组人脑利钠肽 心肾综合征 |
| 英文关键词: Heart failure Recombinant form of human brain natriuretic peptide Cardiorenal syndrome |
| 基金项目: |
|
| 摘要点击次数: 672 |
| 全文下载次数: 847 |
| 中文摘要: |
| 心力 衰竭同 时合并肾功能不全或肾功能恶化， 也称为 心肾综合征， 是临床心血管疾病的终末阶段， 患者的死亡率及再住院
率较高。 重组人脑利钠肽是利用 重组 DNA 技术制成的人脑利钠肽，与内 源性脑利 钠肽具有相同 的药理作用 :扩张血管， 降低右房
压力及肺毛细血管楔压， 减轻心脏负 荷， 可以选择性扩张冠状动脉，增加冠状动脉的血流量； 通过激活心肌细胞内 cGMP 依赖的
蛋白激酶 PKG-1，产生细胞应激性保护，降低心肌耗氧量； 抑制 RAAS 及 SNS，抑制反射性心动过速和血管收缩， 无正性肌力 作用
和正性心率作用，抑制心脏重塑。 重组人脑利 钠肽作用 于肾脏可以改善肾脏血流灌注， 提高肾小球滤过率。 虽 然重组人脑利钠肽
治疗心力衰竭取得了 很好地效果， 但其对心力衰竭患者肾功能的影响仍存在争议。 重组人脑利钠肽具有多 重活性且不良反应少，
已被许多 专家视为很有应用 前景的新药。 |
| 英文摘要: |
| Heart failure with renal insufficiency is the end stage of clinical cardiovascular disease, which will lead to complex
clinical syndrome. Thus the high mortality and readmission rates are often seen in those patients. Recombinant human brain natriuretic
peptide (rhBNP) has the same pharmacological effects with endogenous natriuretic peptide on vasodilation, increased natriuresis and
dieresis. All these mechanism focus on vasodilation production, physical blood pressure and fluid reduction, which result in a reduction in
both preload and afterload. Finally, it relieve various symptoms such as dyspnea or edema and improve haemodynamic functions in
patients who treated with rhBNP beside standard therapy. There is no side-effect like increased heart rate or myocardial contractility.
Although recombinant human brain natriuretic peptide in treatment of heart failure has obtained good curative effect, there's a lot of
debates about whether it will get the same effect on those with renal insufficiency. rhBNP has multiple activity and fewer adverse
reactions, had been considered a very promising drug by many experts. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
